Stocks & Investing
Stocks and Investing
Stocks and Investing
Mon, April 3, 2023
[ Mon, Apr 03rd 2023
] - WOPRAI
[ Mon, Apr 03rd 2023
] - WOPRAI
[ Mon, Apr 03rd 2023
] - WOPRAI
[ Mon, Apr 03rd 2023
] - WOPRAI
[ Mon, Apr 03rd 2023
] - WOPRAI
[ Mon, Apr 03rd 2023
] - WOPRAI
[ Mon, Apr 03rd 2023
] - WOPRAI
[ Mon, Apr 03rd 2023
] - WOPRAI
[ Mon, Apr 03rd 2023
] - WOPRAI
[ Mon, Apr 03rd 2023
] - WOPRAI
[ Mon, Apr 03rd 2023
] - WOPRAI
[ Mon, Apr 03rd 2023
] - WOPRAI
Sat, April 1, 2023
[ Sat, Apr 01st 2023
] - WOPRAI
Fri, March 31, 2023
[ Fri, Mar 31st 2023
] - WOPRAI
[ Fri, Mar 31st 2023
] - WOPRAI
[ Fri, Mar 31st 2023
] - WOPRAI
[ Fri, Mar 31st 2023
] - WOPRAI
[ Fri, Mar 31st 2023
] - WOPRAI
[ Fri, Mar 31st 2023
] - WOPRAI
[ Fri, Mar 31st 2023
] - WOPRAI
[ Fri, Mar 31st 2023
] - WOPRAI
[ Fri, Mar 31st 2023
] - WOPRAI
[ Fri, Mar 31st 2023
] - WOPRAI
[ Fri, Mar 31st 2023
] - WOPRAI
[ Fri, Mar 31st 2023
] - WOPRAI
[ Fri, Mar 31st 2023
] - WOPRAI
[ Fri, Mar 31st 2023
] - WOPRAI
[ Fri, Mar 31st 2023
] - WOPRAI
[ Fri, Mar 31st 2023
] - WOPRAI
Judah Frommer Maintained (CADL) at Buy with Decreased Target to $7 on, Mar 31st, 2023
Judah Frommer of Credit Suisse, Maintained "Candel Therapeutics, Inc." (CADL) at Buy with Decreased Target from $8 to $7 on, Mar 31st, 2023.
Judah has made no other calls on CADL in the last 4 months.
There is 1 other peer that has a rating on CADL. Out of the 1 peers that are also analyzing CADL, 0 agree with Judah's Rating of Hold.
This is the rating of the analyst that currently disagrees with Judah
- Vernon Bernardino of "HC Wainwright & Co." Initiated at Strong Buy and Held Target at $11 on, Friday, December 2nd, 2022
